LEI: 549300Q7EXQQH6KF7Z84
24 May 2024
RTW Biotech Opportunities Ltd
Cancellation of Own Shares
Following approval at the Annual General meeting held on 16 May 2024 the Company has today cancelled 48,322,863 of its own shares that were previously held by RTW Biotech Opportunities Operating Ltd ("RTW OpCo") for nil consideration. Such Shares were issued to RTW Opco pursuant to the scheme of reconstruction of Arix Bioscience plc ("Arix"), as described in the Company's prospectus dated 5 January 2024.
Further details are set out below:
Number of shares held as treasury shares following this cancellation: 9,853,791
Total shares in issue excluding treasury shares following this cancellation: 336,113,649
The above figure of 336,113,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For Further Information:
| RTW Investments, LP | +44 (0)20 7959 6361 biotechopportunities@rtwfunds.com |
| Woody Stileman, Managing Director Krisha McCune, Director, Investor Relations |
|
|
|
|
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.